Similar articles

• Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs.

  Pilotto A, Franceschi M, Leandro G, Paris F, Cascavilla L, Longo MG, Niro V, Andriulli A, Scarcelli C, Di Mario F. Pilotto A, et al. Aliment Pharmacol Ther. 2004 Nov 15;20(10):1091-7. doi: 10.1111/j.1365-2036.2004.02246.x. Aliment Pharmacol Ther. 2004. PMID: 15569111
• Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users.

  Vergara M, Catalán M, Gisbert JP, Calvet X. Vergara M, et al. Aliment Pharmacol Ther. 2005 Jun 15;21(12):1411-8. doi: 10.1111/j.1365-2036.2005.02444.x. Aliment Pharmacol Ther. 2005. PMID: 15948807 Review.
• Eradication therapy of Helicobacter pylori directly induces apoptosis in inflammation-related immunocytes in the gastric mucosa--possible mechanism for cure of peptic ulcer disease and MALT lymphoma with a low-grade malignancy.

  Ohara T, Kanoh Y, Higuchi K, Arakawa T, Morisita T. Ohara T, et al. Hepatogastroenterology. 2003 May-Jun;50(51):607-9. Hepatogastroenterology. 2003. PMID: 12828043
• Current indications for acid suppressants in Helicobacter pylori -negative ulcer disease.

  Howden CW, Leontiadis GI. Howden CW, et al. Best Pract Res Clin Gastroenterol. 2001 Jun;15(3):401-12. doi: 10.1053/bega.2001.0187. Best Pract Res Clin Gastroenterol. 2001. PMID: 11403535 Review.
• Usefulness of proton pump inhibitor (PPI) maintenance therapy for patients with H. pylori-negative recurrent peptic ulcer after eradication therapy for H. pylori: pathophysiological characteristics of H. pylori-negative recurrent ulcer scars and beyond acid suppression by PPI.

  Ohara T, Morishita T, Suzuki H, Masaoka T, Ishii H. Ohara T, et al. Hepatogastroenterology. 2004 Mar-Apr;51(56):338-42. Hepatogastroenterology. 2004. PMID: 15086153